Peer-Reviewed Publications

      Comet assay and air-liquid interface exposure system: A new combination to evaluate genotoxic effects of cigarette whole smoke in human lung cell lines

      Weber, S.; Hebestreit, M.; Wilms, T.; Conroy, L. L.; Rodrigo, G.
      Published
      Jul 8, 2013
      DOI
      10.1016/j.tiv.2013.06.016
      PMID
      23845897
      Link to publication
      Topic
      Summary

      Over the past three decades, the genotoxic effects of cigarette smoke have generally been evaluated in non-human cell models after exposure to particulate phase, gas phase, or cigarette smoke condensate, rather than the whole smoke aerosol itself. In vitro setups using human cell lines and whole smoke exposure to mimic actual aerosol exposure should more accurately reflect human cigarette smoke exposure. We investigated the VITROCELL® 24 air–liquid interface exposure system in combination with the comet assay to assess DNA damage in two different human lung epithelial cell lines exposed to whole smoke. Results showed a repeatable and reproducible dose–response relationship between DNA damage and increased whole smoke dose in both cell lines. Thus, the combination of the comet assay with the VITROCELL® 24 represents a valuable new in vitro test system to screen and assess DNA damage in human lung cells exposed to whole smoke.

      Related Publications

      Key Challenges and Recommendations for In Vitro Testing of Tobacco Products for Regulatory Applications: Consideration of Test Materials and Exposure Parameters

      Pre-clinical Toxicology

      Quantification and mapping of alkylation in the human genome reveal single nucleotide resolution precursors of mutational signatures

      Pre-clinical Toxicology

      An in vitro evaluation of e-vapor products: The contributions of chemical adulteration, concentration, and device power

      Pre-clinical Toxicology

      Tobacco heating system has less impact on bone metabolism than cigarette smoke

      Pre-clinical Toxicology

      Novel α7 nicotinic acetylcholine receptor modulators as potential antitussive agents

      Pre-clinical Toxicology

      Differentiating the neuropharmacological properties of nicotinic acetylcholine receptor-activating alkaloids

      Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.